Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity

Cell Death and Disease

Volumn 3, Issue 3, 2012, Pages

  Siegemund, M ^a   Pollak, N ^a   Seifert, O ^a   Wahl, K ^b   Hanak, K ^b   Vogel, A ^b   Nussler, A K ^c   Gottsch D ^a   Munkel S ^a   Bantel, H ^b   Kontermann, R E ^a   Pfizenmaier, K ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apo2L; Apoptosis; EGFR targeting; scFv; TRAIL oligomers

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; CETUXIMAB; CYCLOHEXIMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; SINGLE CHAIN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; UNCLASSIFIED DRUG; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; DEATH RECEPTOR 4; DEATH RECEPTOR 5; SINGLE CHAIN FV FRAGMENT SINGLE CHAIN TRAIL FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FEMALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL STRAIN HEK293; CELL STRAIN HEPG2; COLON TUMOR; DIMERIZATION; DRUG EFFECT; GENETICS; HUMAN; LEUKEMIA CELL LINE; METABOLISM; NUDE MOUSE; TUMOR CELL LINE; XENOGRAFT; CANCER CELL; COLON CARCINOMA; CONTROLLED STUDY; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIMERIZATION; HEK293 CELLS; HEP G2 CELLS; HUMANS; JURKAT CELLS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS;

EID: 84859342644     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.29     Document Type: Article

References (43)

1. Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011; 11: 431-449.
2. Holland PM. Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL. Cancer Lett 2011; e-pub ahead of print 8 January 2011; doi:10.1016/j.canlet. 2010.11.001.
3. Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL. Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). ASCO Meeting Abstracts 2010; 28: 8104.
4. Hörnle M, Peters N, Thayaparasingham B, Vörsmann H, Kashkar H, Kulms D. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene 2011; 30: 575-587.
5. Volkmann M, Schiff JH, Hajjar Y, Otto G, Stilgenbauer F, Fiehn W et al. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med 2001; 79: 594-600. (Pubitemid 32938388)
6. Chan C, Yau T, Jin D, Wong C, Fan S, Ng IO. Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 4140-4149. (Pubitemid 38812494)
7. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
8. Koehler B, Urbanik T, Vick B, Boger R, Heeger S, Galle P et al. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 2009; 15: 5924-5935.
9. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005; 42: 588-597. (Pubitemid 41233651)
10. Chen K, Yeh P, Hsu C, Hsu C, Lu Y, Hsieh H et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009; 284: 11121-11133.
11. Sun W, Nelson D, Alberts SR, Poordad F, Leong S, Teitelbaum UR et al. Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis. J Clin Oncol 2011; 29 (Suppl 4) abstract 261.
12. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJS, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005; 65: 11265-11270. (Pubitemid 41821680)
13. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006; 103: 8634-8639. (Pubitemid 43878072)
14. ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M et al. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009; 23: 1389-1397.
15. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
16. Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H et al. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis 2010; 1: e68.
17. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167. (Pubitemid 30428195)
18. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37: 343-349. (Pubitemid 23300519)
19. Ng M, Cunningham D. Cetuximab (Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract 2004; 58: 970-976. (Pubitemid 39642620)
20. Doody JF, Wang Y, Patel SN, Joynes C, Lee SP, Gerlak J et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 2007; 6: 2642-2651. (Pubitemid 350058145)
21. Wajant H, Moosmayer D, Wüest T, Bartke T, Gerlach E, Schönherr U et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20: 4101-4106. (Pubitemid 32681615)
22. Berg D, Stühmer T, Siegmund D, Müller N, Giner T, Dittrich-Breiholz O et al. Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways. FEBS J 2009; 276: 6912-6927.
23. Holliger P, Prospero T, Winter G. Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444-6448. (Pubitemid 23207229)
24. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269: 27595-27602. (Pubitemid 24346592)
25. Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kühnle M, Gerspach J, Sterns T et al. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008; 180: 8176-8183.
26. Gerspach J, Wajant H, Pfizenmaier K. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl Cell Differ 2009; 49: 241-273.
27. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004; 109: 281-290. (Pubitemid 38240933)
28. Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen B, Fey GH et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005; 65: 3380-3388. (Pubitemid 40524623)
29. Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett 2011; e-pub ahead of print 13 January 2011; doi:10.1016/ j.canlet.2010.12.019.
30. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213. (Pubitemid 28189110)
31. Koschny R, Walczak H, Ganten TM. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 2007; 85: 923-935. (Pubitemid 47282789)
32. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430. (Pubitemid 37328939)
33. Song JH, Tse MCL, Bellail A, Phuphanich S, Khuri F, Kneteman NM et al. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007; 67: 6946-6955. (Pubitemid 47105542)
34. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007; 6: 2591-2599. (Pubitemid 47480425)
35. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567. (Pubitemid 30305907)
36. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006; 12: 2640-2646.
37. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007; 13: 3403-3412. (Pubitemid 46944929)
38. Nussler AK, Nussler NC, Merk V, Brulport M, Schormann W, Hengstler JG. The Holy grail of hepatocyte culturing and therapeutic use. In: Santin M (ed). Regenerative Medicine Today. Springer International: Berlin, Germany, 2009, pp: 283-320.
39. Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Müller D et al. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 2010; 23: 827-834.
40. Benedict CA, MacKrell AJ, Anderson WF. Determination of the binding affinity of an anti- CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 1997; 201: 223-231. (Pubitemid 27086719)
41. Wüest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 2002; 21: 4257-4265. (Pubitemid 34753832)
42. Seidel N, Volkmann X, Länger F, Flemming P, Manns MP, Schulze-Osthoff K et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 2005; 42: 113-120. (Pubitemid 40911318)
43. Kim TH, Youn YS, Jiang HH, Lee S, Chen X, Lee KC. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. Bioconjug Chem 2011; 22: 1631-1637.